A new report reveals Turkey has the lowest access to innovative medicines among 36 European nations. The study, conducted by IQVIA for pharmaceutical industry associations, found Turkish patients have limited access to recently developed treatments compared to their counterparts elsewhere in Europe. The report highlights a significant disparity in availability, with a smaller proportion of new drugs reaching the Turkish market. This lack of access is attributed to factors not detailed in the provided text, but suggests challenges in the country’s healthcare system regarding the adoption of new pharmaceuticals. The findings were released by the Association of Research-Based Pharmaceutical Companies (AIFD) and the European Federation of Pharmaceutical Industries and Associations. Further details regarding the specific reasons for this ranking and potential solutions were not immediately available.